Tubulis GmbH’s Post

Did you know? Jarosław Kasprowicz, PhD, MBA, Head of Clinical Operations at Clinmark, who will be representing us at the upcoming Bio Convention in San Diego, boasts over 12 years of extensive expertise in clinical trials setup, monitoring, and management across diverse therapeutic fields. With his wealth of experience, he's ready to explore collaborations and discuss how Clinmark can elevate your research. Don't miss this opportunity to connect and schedule a meeting with him! #Clinmark #BioConvention #SanDiego #ClinicalResearch #CebioForum #PolishTradeandInvestmentAgncy

Looking to accelerate drug discovery? Meet @Paradigm4 at #ASHG23 and discover how we’re increasing velocity in the search for the right druggable targets #PharmaResearch #DrugDiscovery #ASHG23 #bioinformatics #datascience Click here to connect: https://lnkd.in/gma9j8B4

Check out the latest from Outcome Capital on the state of #lifesciences: - JPM deal making sets the table for a active 2024 - Rare diseases assets remain M&A target of large strategics, commanding significant premiums and driving billion-dollar deals - #healthtech starts off 2024 on the upswing with transformative acquisitions from Cardinal Health and HCSC - Despite reversion to pre-COVID investment volumes, 2024 began with numerous upsized Series A financings #lifesciences #biotechnology #investmentbanking #meddevice #diagnostics #digitalhealth #pharmaservices #mergersandacquisitions

Opthea announced they will receive remaining US$35m funding under the Development Funding Agreement (DFA) with Carlyle and its life science franchise Abingworth, as well as a further US$50m financing under an Amended DFA to include a new co-investor This financing is non-dilutive to shareholders, with no equity issued to Carlyle, Abingworth or the new co-investor Investment driven by the potential of sozinibercept (OPT-302) to provide superior visual outcomes for wet AMD patients and to provide a multi-billion-dollar commercial opportunity Dr. Fred Guerard, Chief Executive Officer of Opthea Limited, commented, “We are extremely pleased with this funding that demonstrates investors’ confidence in sozinibercept and its potential for future clinical, regulatory and commercial success. Both global pivotal trials in wet AMD (COAST and ShORe) are now over 80% enrolled and aim at confirming the superior efficacy outcomes observed in Opthea’s Phase 2b trial.” Learn more https://lnkd.in/e7hm8Tvr #biotech #investment #wetAMD The Carlyle Group Abingworth

Interested in finding out more about the discovery of bifunctional degraders? Join Dr Rich Boyce, our Senior VP Drug Discovery, at TPD Summit Europe next month to learn how we are using our PROTEINi technology to inform and accelerate small molecule drug design and development. Check out the full agenda here: https://rb.gy/evo3yv #DrugDiscovery #TPD #ProteinDegradation

Importing your clinical trial data has never been easier. Don't miss an opportunity to streamline your clinical study management. Check out this week's Quick Tip, and let Egnyte make your studies shine! 💡 Learn more at Egnyte University. 🎓 bit.ly/3QXF2mt #LifeSciences #BioTech

Early phase clinical trials are critical for assessing the safety, dosage, and efficacy of new treatments. CenExel supports these trials with its state-of-the-art facilities, experienced researchers, and robust infrastructure. By offering comprehensive services—from protocol design to data analysis—CenExel ensures the efficient and ethical conduct of trials, accelerating the development of innovative therapies! Want to know more? --> cenexel.com #CenExel #ClinicalResearch #ClinicalTrials

How do you find, identify, and validate hits? 🤔 These are questions that anyone in #DrugDiscovery will be familiar with – and ones we aimed to tackle in our recent Interaction Analysis Masterclass! Our experts Edward A. FitzGerald, Marta Janczuk-Richter, and Stoyan Milev explained how ITC and GCI can be used as complementary technologies for all your early-stage drug discovery needs. Missed it? No worries – you can catch up on the masterclass here 🔗https://lnkd.in/dDcPubrk #DrugDiscovery #InteractionAnalysis #Masterclass #ITC #GCI

Exciting news from our Sydney site! Meet our new laboratory partner Crux Biolabs. As a trusted industry leader in laboratory management, this partnership will enhance our ability to drive cutting-edge research and deliver top-notch services. What does this mean for Emeritus Research? 1. Expanded Service Offering: Rest assured; we'll continue providing the same high-quality services you expect from Emeritus Research. 2. PBMC Isolation: We're bringing PBMC isolation as part of our laboratory expansion, ensuring our team have timely access to crucial complex services right here in Sydney. You can expect the same techniques used in our Melbourne laboratory, rapid turnaround times, and reduced reliance on courier services for clinical samples. 3. Increased Space: Crux Biolabs is expanding our laboratory facilities, equipping us to take on even more clinical research projects. We'll have access to new equipment and additional skilled laboratory staff. 4. Enhanced Collaboration: This partnership paves the way for enhanced collaboration and interdisciplinary research opportunities with Crux Biolab’s bioanalytical experts working alongside Emeritus Research. We are immensely excited about the future of this partnership. It's a significant step forward for our Sydney site, reinforcing our commitment to excellence in research. Stay tuned for updates on our progress and the incredible research opportunities this collaboration will bring. #Partnership #ResearchInnovation #CRUXBiolabs #ScienceCollaboration #EmeritusResearch